Paratek Pharma

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.

Data highlight Paratek’s commitment to further understanding safety and efficacy of NUZYRA® (omadacycline) in unique population subsets Data highlight Paratek’s commitment to further understanding safety and efficacy of NUZYRA® (omadacycline) in unique population subsets

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019

Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

Paratek Pharmaceuticals (PRTK) Catches Eye: Stock Jumps 10.2%

BOSTON, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at 21st Annual H.C. Wainwright Global Investment Conference on Monday, September 9 at 11:15 a.m. ET at the Lotte New York Palace Hotel in New York.

Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

Once-daily NUZYRA is non-inferior to twice-daily oral linezolid for the treatment of adults with ABSSSI, including MRSA; confirms efficacy and safety of oral-only formulation Once-daily NUZYRA is non-inferior to twice-daily oral linezolid for the treatment of adults with ABSSSI, including MRSA; confirms efficacy and safety of oral-only formulation

The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections

BOSTON, Aug.  26, 2019  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at Baird’s 2019 Global Healthcare Conference on Wednesday, September 4 at 3:10 p.m. ET at the InterContinental New York Barclay in New York.

Paratek Pharmaceuticals to Present at Robert W. Baird’s 2019 Global Healthcare Conference

Akcea Therapeutics

AMAG Pharmaceuticals

Eidos Therapeutics Inc

Ligand Pharmaceuticals

MannKind

Moderna

Viking Therapeutics

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower profitability for the sector as a whole.

8 Biotechs Being Choked by Short Sellers

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q2 2019 Results - Earnings Call Transcript

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Paratek Pharmaceuticals (PRTK) Q2 Earnings Expected to Decline

Paratek Pharmaceuticals, Inc. (PRTK) CEO Michael Bigham on Q1 2019 Results - Earnings Call Transcript

News for Paratek Pharma Stock (PRTK)